T. cruzi Polypeptide Combinations for Diagnostic Accuracy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Trypanosoma cruzi infection, such as serological tests, face challenges in distinguishing active infections from resolved infections, leading to inaccurate diagnosis and hindering the broader use of drugs and development of new treatments.
Innovation Solution
The use of combinations of Trypanosoma cruzi polypeptides and fusion proteins that are antigenic to T. cruzi antibodies, specifically designed to improve detection by enhancing antibody binding affinity and specificity, allowing for more accurate diagnosis and monitoring of infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional serological tests using crude or semi-purified parasite preparations are used, then the tests are convenient and blood is easily accessible, but the tests lack sensitivity and cannot reliably distinguish active infections from resolved infections
Solution Approach 1:
The patent extracts and isolates specific antigenic polypeptides (such as TcCBP, TcTGP, TcCLAG-2) from the complex parasite preparation, using only these specific components in the diagnostic test. This extraction of essential elements from the crude preparation maintains test effectiveness while eliminating unnecessary complexity and improving reliability by focusing on specific antigens that distinguish active from resolved infections
Solution Approach 2:
The patent divides the complex parasite antigen into multiple distinct polypeptide components and uses combinations of these segmented antigens in the diagnostic test. By segmenting the antigen and using specific combinations (e.g., TcCBP with TcTGP, or TcCBP with TcCLAG-2), the test achieves higher diagnostic accuracy in distinguishing infection states while maintaining a manageable test structure
2Measurement precision
If single antigens or bulk parasite antigens are used in serological tests, then the test format is simple, but the sensitivity is insufficient and antibody detection is unreliable
Solution Approach 1:
The patent merges multiple specific polypeptide antigens into combination formulations (e.g., TcCBP + TcTGP, TcCBP + TcCLAG-2, or all three together). This merging of complementary antigens enhances the overall sensitivity and specificity of antibody detection, allowing the test to reliably distinguish active from resolved infections while managing complexity through rational antigen selection
Solution Approach 2:
The patent creates composite antigen materials by combining specific polypeptides with defined properties (molecular weight, antigenic activity) in controlled ratios. These composite antigen formulations provide enhanced measurement precision for antibody detection compared to single antigens, while the composite structure allows for standardized manufacturing and quality control
3Reliability
If crude parasite preparations are used in diagnostic tests, then the manufacturing process is simpler, but the diagnostic dependability is poor and results are inconsistent
Solution Approach 1:
The patent extracts specific polypeptide antigens (TcCBP, TcTGP, TcCLAG-2) from crude parasite preparations using purification techniques that isolate these essential diagnostic components. This extraction improves diagnostic dependability by eliminating variable contaminants present in crude preparations, while the targeted nature of the extraction maintains reasonable manufacturing efficiency
Solution Approach 2:
The patent changes the physical and chemical parameters of the antigen material by purifying specific polypeptides to defined molecular weights and purities. This parameter change from crude to purified antigens significantly improves diagnostic reliability and result consistency, while the standardized purification parameters enable reproducible manufacturing across different batches and facilities
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These combinations enable improved detection of T. cruzi antibodies, facilitating accurate diagnosis and monitoring of infections, thereby aiding in the effective treatment and management of Chagas disease.
Implementation Method 1
combinations of Trypanosoma cruzi polypeptides and fusion proteins that are antigenic to T. cruzi antibodies, specifically designed to improve detection by enhancing antibody binding affinity and specificity
Data Source
AI summary
Combinations of Trypanosoma cruzi polypeptides, fusion protein formed therefrom, and compositions and methods of use thereof for improved detection of antibodies against T. cruzi are disclosed. Preferred polypeptide combinations include two or more polypeptides selected from Table 1, or a variant or fragment thereof. In particularly preferred embodiments, the polypeptide combinations include the two polypeptide as paired in Table 2 or Table 3, or variants or fragments thereof. Preferably, the one, or more preferably both, of the polypeptides are antigenic to T. cruzi antibodies. The polypeptide combination can unfused or fused for form fusion proteins. Methods of using the disclosed compositions, including methods of detecting anti-T. cruzi antibodies, diagnosing T. cruzi infections, and monitoring disease status and treatment efficacy are also provided.